Polymer Capital Management HK LTD Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Polymer Capital Management HK LTD bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,313 shares of the biopharmaceutical company’s stock, valued at approximately $2,427,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. Regeneron Pharmaceuticals Inc. bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,045,822,000. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $577,941,000. Raymond James Financial Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $61,160,000. Finally, Proficio Capital Partners LLC lifted its position in Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after acquiring an additional 192,916 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $235.74 on Friday. The firm has a fifty day moving average of $259.03 and a 200-day moving average of $260.23. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ALNY shares. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Scotiabank increased their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.